Cretostimogene Grenadenorepvec: Mechanism and Rationale

Among the intravesical agents under investigation for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), cretostimogene grenadenorepvec occupies a mechanistically distinct position as a replicating oncolytic immunotherapy—a category that differs meaningfully from both cytotoxic chemotherapy and non-replicating gene therapy approaches. In the second segment of this series, Mark D. Tyson II, MD, MPH, a professor of urology at Mayo Clinic in Phoenix, Arizona, reviews the mechanism of action underlying cretostimogene's activity and the early clinical rationale that supported its regulatory designations.

Cretostimogene is engineered to preferentially replicate within cancer cells harboring Rb-E2F pathway alterations—a genetic disruption that is particularly prevalent in carcinoma in situ (CIS). Replication within these malignant cells results in direct tumor cell lysis and the release of tumor-associated antigens into the local microenvironment. Simultaneously, the virus expresses GM-CSF, a transgene designed to recruit and activate antigen-presenting cells, thereby amplifying a broader adaptive immune response against the tumor. Tyson describes this combination of local cytolytic activity and immune system engagement as especially well suited to NMIBC, a disease localized to the bladder where strong intravesical activity can be achieved without the systemic toxicity burden associated with systemic immunotherapy.

The early phase 1 and phase 2 clinical experience with cretostimogene—including data from the BOND2 study in BCG-exposed and BCG-unresponsive patients—demonstrated that the agent could be delivered on a practical intravesical schedule with a toxicity profile predominantly limited to grade 1 and 2 local bladder symptoms. Tyson notes that the complete response rates observed in BCG-unresponsive patients in the earlier phase work provided the rationale for advancing to the phase 3 BOND-003 program. These early data, combined with the recognized unmet need in the BCG-unresponsive setting, supported the FDA's decisions to grant cretostimogene both Breakthrough Therapy and Fast Track Designations.